Article

Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling

2023-06-30

Abstract excerpt

Antibodies with lambda light chains ( λ -antibodies) are generally considered to be less developable than those with kappa light chains ( κ -antibodies), leading to substantial systematic biases in drug discovery pipelines. This has contributed to kappa dominance amongst clinical-stage therapeutics. However, the identification of increasing numbers of epitopes preferentially engaged by λ -antibodies shows there...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2a82858e-40f5-5676-b194-19f617c854af
DOI: 10.1101/2023.06.28.546839

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profilingDOI 10.1101/2023.06.28.546839Read

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approachesSemantic proximity Read

The Therapeutic Antibody Profiler (TAP): Five Computational Developability GuidelinesSemantic proximity Read

Intrinsic physicochemical profile of marketed antibody-based biotherapeuticsSemantic proximity Read

Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developabilitySemantic proximity Read

A comparison of the binding sites of antibodies and single-domain antibodiesSemantic proximity Read

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies.Semantic proximity Read

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity Read

Data-driven evaluation of suitable immunogens for improved antibody selectionSemantic proximity Read

AI-Guided Precision in Antibody Humanization: Structural Modeling to Minimize Immunogenicity and Preserve EfficacySemantic proximity Read

Antibody immunogenicity prediction and optimization with ImmunoSeqSemantic proximity Read

Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regionsSemantic proximity Read

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read